Fenfluramine in CDKL5 Deficiency Disorder (CDD)

PHASE2CompletedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

October 29, 2019

Primary Completion Date

August 30, 2022

Study Completion Date

October 24, 2022

Conditions
CDD
Interventions
DRUG

Fenfluramine Hydrochloride

Oral aqueous solution of fenfluramine hydrochloride buffered to pH 5 and provided in concentrations of 2.5 mg/mL. Manufactured by Andersonbrecon, Inc. on behalf of Zogenix International Limited.

Trial Locations (1)

10016

New York Langone Health Comprehensive Epilespy Center, New York

All Listed Sponsors
lead

NYU Langone Health

OTHER

NCT03861871 - Fenfluramine in CDKL5 Deficiency Disorder (CDD) | Biotech Hunter | Biotech Hunter